# Shanghai Cell Therapy Group Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-cell-therapy-group-co

- Industry: Healthcare
- Headquarters: Shanghai, China
- Website: www.shcell.com
- Total disclosed funding: $279M
- Latest round: Series D (Mar 24, 2021)
- Investors on record: 8

## About

Shanghai Cell Therapy Group Co., Ltd. is a pioneering company in the field of cellular technology, dedicated to enhancing human health through innovative therapies and products tailored for longevity and quality of life.Established in 2013 and headquartered in Shanghai, China, Shanghai Cell Therapy Group Co., Ltd. specializes in cellular medical health solutions. The company was founded by Jiewei Li, who has a background in cellular therapy innovations. The firm has successfully secured a total of CNY 500 million in Series D funding on March 24, 2021, from investors including CCB International, Haier Capital, and Jiuzhou Venture, significantly bolstering its financial foundation for future growth.  Shanghai Cell Therapy Group is recognized as the first and only company in China to cover the entire value chain of cellular medical health. Their core offerings include advanced cellular rejuvenation products and therapies aimed at enhancing the quality of human life and contributing to longevity. By leveraging breakthroughs in cellular therapy technologies, they develop transformative solutions for curing cancers and age-related diseases. The company primarily serves healthcare providers and patients, focusing on preventing and intervening in health conditions associated with aging, thereby promoting vitality and well-being.Shanghai Cell Therapy Group generates revenue through structured B2B partnerships with healthcare institutions and clinics. Their revenue streams are derived from the sale of cellular rejuvenation therapies and innovative treatment solutions, with contracts established directly with healthcare providers who incorporate these advanced products into their treatment offerings. The pricing model is aligned with industry standards, reflecting the premium positioning of these medical products.Following their most recent funding round on March 24, 2021, which raised CNY 500 million, Shanghai Cell Therapy Group Co., Ltd. plans to accelerate its product research and development. The company is focused on designing new cellular therapies aimed at expanding their treatment solutions. Additionally, there are plans to explore international markets to broaden their reach beyond China, targeting specific regions yet to be disclosed. This strategic approach aims to enhance their standing in the global cellular therapy market.

## Funding rounds

- Series D, Mar 24, 2021, $77M — CCB International, Jiuzhou Venture, Haier Capital
- Series C, Dec 7, 2018, $135M — Legend Capital, China Pacific Insurance (Group) Co. Ltd., Ciit Asset Management, Haier Capital, Shanghai Anting Industrial Development
- Series C, Nov 26, 2018, $40M — Legend Capital, Ciit Asset Management
- Series B, Apr 1, 2016, $28M — Legend Capital, Shanghai Yaoji Playing Card Co., Ltd

## Investors

- Legend Capital — Series B, Series C
- Shanghai Yaoji Playing Card Co., Ltd — Series B
- Ciit Asset Management (https://capitalatlas.ai/funds/ciit-asset-management) — Series C
- China Pacific Insurance (Group) Co. Ltd. — Series C
- Haier Capital (https://capitalatlas.ai/funds/haier-capital) — Series C, Series D
- Shanghai Anting Industrial Development — Series C
- CCB International (https://capitalatlas.ai/funds/ccb-international) — Series D
- Jiuzhou Venture (https://capitalatlas.ai/funds/jiuzhou-venture) — Series D